In particular, PPRHs interfering with promoter activation (HpMYC-G4-PR-C) and transcription (HpMYC-I1-T) dose- and time-dependently regulated these cancer cells and decreased MYC and downstream Cyclin D1 expression at concentrations as low as 25 nM. This evidence concerns the gene MYC and cancer.